Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

181. Molecular characterization and pathogenesis of gastrointestinal stromal tumor Full Text available with Trip Pro

Molecular characterization and pathogenesis of gastrointestinal stromal tumor Most gastrointestinal stromal tumors (GISTs) harbor activating mutations in the receptor tyrosine kinase gene KIT or platelet-derived growth factor receptor alpha (PDGFRA), and the resultant activation of downstream signals plays a pivotal role in the development of GISTs. The sites of the tyrosine kinase gene mutations are associated with the biological behavior of GISTs, including risk category, clinical outcome (...) and drug response. Mutations in RAS signaling pathway genes, including KRAS and BRAF, have also been reported in KIT/PDGFRA wild-type GISTs, though they are rare. Neurofibromin 1 (NF1) is a tumor suppressor gene mutated in neurofibromatosis type 1. Patients with NF1 mutations are at high risk of developing GISTs. Recent findings suggest that altered expression or mutation of members of succinate dehydrogenase (SDH) heterotetramer are causally associated with GIST development through induction

2018 Translational gastroenterology and hepatology

182. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies Full Text available with Trip Pro

gastrointestinal GI malignancies and the emerging data on immune biomarkers and SBRT, with a focus on pancreatic and liver cancer. (...) Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies The role of external beam radiation therapy (EBRT) in the management of upper gastrointestinal malignancies is constantly evolving. As radiation therapy techniques improve and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT) allows a high dose of radiation to be delivered

2018 Biomedicines

183. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Full Text available with Trip Pro

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea, and mucositis associated with dacomitinib, an oral irreversible pan-human epidermal growth factor receptor (HER) inhibitor, in development for advanced non-small (...) -cell lung cancer (NSCLC).Patients with advanced NSCLC treated with dacomitinib were enrolled in two cohorts. Cohort I patients were randomized 1:1 to receive oral doxycycline or placebo (4 weeks). Cohort II patients received oral VSL#3 probiotic plus topical alclometasone. Primary end points for Cohorts I and II were incidence of all grade and grade ≥2 SDAEI in the first 8 weeks of treatment and quality of life (QoL) assessed by the Skindex-16 survey. Additional primary end points for Cohort II

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

184. Primary care: Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients

care Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients Carlo Senore 1 , Ulrike Haug 2 , 3 Statistics from Altmetric.com Commentary on: Westwood M, Lang S, Armstrong N, et al . Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med 2017 Oct 24;15:189. Context Efforts (...) aimed to increase awareness of colorectal cancer (CRC) symptoms and to reduce the proportion of cases diagnosed following an emergency presentation might result in a substantial increase in the demand for diagnostic colonoscopies, exceeding the available endoscopy capacity. The aim of this systematic review was to analyse the diagnostic performance of quantitative faecal immunochemical test (FIT) as a triage test for patients with lower abdominal symptoms. 1 Methods This is a review of diagnostic

2018 Evidence-Based Medicine

185. Revised Australian national guidelines for colorectal cancer screening: family history

Revised Australian national guidelines for colorectal cancer screening: family history Revised Australian national guidelines for colorectal cancer screening: family history | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Revised Australian national guidelines for colorectal cancer screening: family history Mark A Jenkins, Driss Ait Ouakrim, Alex Boussioutas, John L Hopper, Hooi C Ee, Jon D Emery, Finlay A Macrae, Albert Chetcuti, Laura Wuellner and D James B St John Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00142 Published online: 29 October 2018 Topics Abstract Introduction: Screening is an effective means for colorectal cancer prevention

2018 MJA Clinical Guidelines

186. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Full Text available with Trip Pro

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. 29718089 2018 12 20 1569-8041 29 11 2018 Nov 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. 2270 10.1093

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

187. Consensus and controversies regarding follow?up after curative intent treatment of non?metastatic colorectal cancer: a synopsis of guidelines used in countries represented in ESCP Full Text available with Trip Pro

Consensus and controversies regarding follow?up after curative intent treatment of non?metastatic colorectal cancer: a synopsis of guidelines used in countries represented in ESCP Consensus and controversies regarding follow‐up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology - Bastiaenen - 2019 - Colorectal Disease - Wiley Online Library By continuing to browse this site (...) , you agree to its use of cookies as described in our . Search within Search term Search term Systematic Review Consensus and controversies regarding follow‐up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Corresponding Author E-mail address: Department of Surgery, Aarhus University

2018 Palliative Care Evidence Review Service (PaCERS)

188. Colorectal cancer

, radiotherapy, resection of metastases) has increased survival in selected cases. Definition The majority of colorectal cancers are adenocarcinomas derived from epithelial cells. About 71% of new colorectal cancers arise in the colon and 29% in the rectum. Toms JR, ed. CancerStats monograph 2004. London: Cancer Research; 2004. Less common types of malignant colorectal tumours are carcinoid tumours, GI stromal cell tumours, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal (...) adenocarcinoma with 99% of cancers occurring in people aged 40 years or over. History and exam presence of risk factors increasing age rectal bleeding change in bowel habit rectal mass positive FHx abdominal mass anaemia male sex abdominal pain weight loss and anorexia abdominal distension palpable lymph nodes increasing age APC mutation Lynch syndrome (HNPCC) MYH-associated polyposis hamartomatous polyposis syndromes inflammatory bowel disease obesity acromegaly limited physical activity lack of dietary

2018 BMJ Best Practice

189. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Full Text available with Trip Pro

Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation January 2018 Article Contents Article Navigation Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS T Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center (...) rates and/or a large tumour size reduction (shrinkage) is recommended [II, A]. 13b. There is uncertainty surrounding the best combination to use as only a few trials have addressed this specifically: • In patients with RAS wt disease a cytotoxic doublet plus an anti-EGFR antibody seems to have the best benefit risk/ratio, although the combination of FOLFOXIRI plus or minus bevacizumab may also be considered and, to a lesser extent, a cytotoxic doublet plus bevacizumab [II, A] • In patients with RAS

2018 European Society for Medical Oncology

190. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

. Arai T, Kino I. Morphometrical and cell kinetic studies of normal human colorectal mucosa. Comparison between the proximal and the distal large intestine. Acta Pathol Jpn 1989;39:725–30. 7. Bara J, Nardelli J, Gadenne C, Prade M, Burtin P. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br J Cancer 1984;49:495–501. 8. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal (...) . Dis Colon Rectum 2007;50:1783–99. 3. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779–88. 4. Rothberg PG, Spandorfer JM, Erisman MD, et al. Evidence that c-Myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer 1985;52:629–32. 5. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353–6. 6

2018 CPG Infobase

191. Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer

Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer NHS England » Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer Search Search Menu Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer Document first published: 28 December 2018 Page updated: 28 December 2018 Topic: Publication type: , NHS England will commission selective internal (...) radiation therapy (SIRT) for chemotherapy refractory / intolerant metastatic colorectal cancer in adults in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its

2018 NHS England

192. Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01

in Health Care (IQWiG) - ii - IQWiG employees ? Mareike Kracht ? Tatjana Hermanns ? Julia Kreis ? Fabian Lotz ? Christoph Mosch ? Ulrike Paschen Keywords: Early Detection of Cancer, Mass Screening, Colorectal Neoplasms, Family History, Benefit Assessment, Systematic Review Extract of rapid report S17-01 Version 1.0 Colorectal cancer screening in persons with a family history – update 24 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Key statement Research question (...) Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01 1 Translation of the key statement of the rapid report S17-01 Darmkrebsfrüherkennung bei Personen unter 55 Jahren mit familiärem Risiko – Aktualisierung (Version 1.0; Status: 24 April 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

193. In colonic ρ0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer Full Text available with Trip Pro

approach to identify their changes linked to cancer pathobiology.Human colon cancer HCT116 cells, control and ρ0, were used for qPCR. Bioinformatics analysis: GeneCards, Kaplan-Meier Survival, GENT, cBioPortal.The colonic ρ0 transcriptome was linked with proliferation, DNA replication, survival, tumor morphology, and cancer. Among differentially expressed transcripts, 281 were regulators or biomarkers of human colon cancer especially those with inflammatory microsatellite instability (MSI). We (...) In colonic ρ0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer Mitochondrial reprogramming has emerged as a hallmark of cancer pathobiology. Although it is believed this reprogramming is essential for cancer cells to thrive, how it supports cancer pathobiology is unclear. We previously generated colonic ρ0 (rho0) cells with reduced mitochondrial energy function and acquired their transcriptional signature. Here, we utilized a bioinformatics

2017 Oncoscience

194. Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum Full Text available with Trip Pro

Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms that arise in the gastrointestinal tract and rarely elsewhere in the abdomen. GISTs that develop outside the digestive tract are called extra-GISTs (EGISTs). The incidence of EGISTs is reported to be approximately 10% of all GISTs, and the median age is younger than that of conventional GISTs. EGISTs have similar histology (...) and immunohistochemical features as conventional GISTs, with the majority of them in the omentum and mesentery. Most GISTs harbor a kinase-activating mutation in either KIT or PDGFRA. For EGISTs, the incidence of this type of mutation is 40-50%, which is somewhat lower than for conventional GISTs. EGISTs may have a worse prognosis compared with conventional GISTs with high mitotic indices, large size, and distant metastasis including lymph node involvement. In large abdominal tumors, the visceral origin is almost

2017 Translational gastroenterology and hepatology

195. Endoscopic resection of gastric gastrointestinal stromal tumors Full Text available with Trip Pro

Endoscopic resection of gastric gastrointestinal stromal tumors Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract, and about 60% of them are found in the stomach. With the widespread application of endoscopy and endoscopic ultrasonography (EUS), more and more gastric GISTs are being found in an early stage (with a relative small diameter and no metastasis), giving the chance of complete resection. Endoscopic resection such as endoscopic

2017 Translational gastroenterology and hepatology

196. An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Full Text available with Trip Pro

An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Nongenetic health providers may lack the relevant knowledge, experience, and communication skills to adequately detect familial colorectal cancer (CRC), despite a positive attitude toward the assessment of history of cancer in a family. Specific training may enable them to more optimally refer patients to genetic counseling.The aim of this study was to develop an e (...) module to help surgeons-in-training and gastroenterologists in recognizing a hereditary predisposition in patients with CRC. The e-learning led to improvements in attitude toward the assessment of cancer family history, knowledge on criteria for referral to genetic counseling for CRC, and comprehension of communication skills.©Kirsten Freya Lea Douma, Cora M Aalfs, Evelien Dekker, Pieter J Tanis, Ellen M Smets. Originally published in JMIR Medical Education (http://mededu.jmir.org), 18.12.2017.

2017 JMIR medical education

197. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date

2017 CADTH - Pan Canadian Oncology Drug Review

198. Minimally invasive surgery for gastric gastrointestinal stromal tumors Full Text available with Trip Pro

Minimally invasive surgery for gastric gastrointestinal stromal tumors Minimally invasive surgery has been increasingly performed for gastric gastrointestinal stromal tumors (GIST). In this review we discuss and summarize the current evidence on minimally invasive surgery for gastric GISTs. Laparoscopic resection for gastric GIST has been consistently shown to be associated with superior perioperative outcomes with no compromise in oncological outcomes when compared to open resection (...) in numerous retrospective case-control studies. It has also been shown to be safe and feasible for large tumors or tumors located in unfavorable sites. However, to date, there remains a lack of level 1 evidence from prospective randomized control trials in support of laparoscopic resection.

2017 Translational gastroenterology and hepatology

199. Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies Full Text available with Trip Pro

Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies 29904748 2019 02 26 2452-1094 3 2 2018 Apr-Jun Advances in radiation oncology Adv Radiat Oncol Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies. 216-220 10.1016/j.adro.2017.11.005 Zhen Heming H Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts

2017 Advances in radiation oncology

200. Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Full Text available with Trip Pro

Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with the majority found in the stomach. Surgical resection of the primary gastric GISTs with complete resection margin has been the forefront of curative treatment. The indications for surgical resection are usually related to symptomatic gastric GISTs at presentation. Primary (...) factors (size and mitotic index), patient factors (older age, male) and surgical factors (incomplete resection margin, tumor rupture or spillage) play an important role in stratifying the malignant potential risk of primary gastric GISTs and their chances of recurrence. The understanding of gene mutation driving the growth of GISTs and the discovery of tyrosine kinase inhibitors (TKIs) has altered the surgical management of advanced and metastatic GISTs. Multi-modal therapy incorporating the surgical

2017 Translational gastroenterology and hepatology